The potential role of Bi-specific antibodies in acute myeloid leukemia

Musa Yilmaz; Farhad Ravandi

doi:10.1016/j.beha.2020.101218

The potential role of Bi-specific antibodies in acute myeloid leukemia

Musa Yilmaz, Farhad Ravandi

Leukemia

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Bispecific antibodies consist of antigen recognition sites from two or more antibodies redirecting effector immune cell against target on tumor cells. Rapidly evolving medical technologies enabled engineering and development of recombinant protein products, and this, combined with interest from the pharmaceutical industry, further advanced the bispecific antibody research. Over 50 different types of bispecific antibody constructs are now being manufactured and explored in ongoing or future clinical trials. In this review, we will summarize the available data for bispecific antibodies developed and being investigated for the treatment of patients with acute myeloid leukemia.

Original language	English (US)
Article number	101218
Journal	Best Practice and Research: Clinical Haematology
Volume	33
Issue number	4
DOIs	https://doi.org/10.1016/j.beha.2020.101218
State	Published - Dec 2020

Keywords

AML
BiKE
BiTE
Bispecific antibody
DART
Immunotherapy
Tandem antibody
TriKE

ASJC Scopus subject areas

Oncology
Clinical Biochemistry

Access to Document

10.1016/j.beha.2020.101218

Cite this

@article{0a0ba02f4fc2475fa2f6e1f37104efa2,

title = "The potential role of Bi-specific antibodies in acute myeloid leukemia",

abstract = "Bispecific antibodies consist of antigen recognition sites from two or more antibodies redirecting effector immune cell against target on tumor cells. Rapidly evolving medical technologies enabled engineering and development of recombinant protein products, and this, combined with interest from the pharmaceutical industry, further advanced the bispecific antibody research. Over 50 different types of bispecific antibody constructs are now being manufactured and explored in ongoing or future clinical trials. In this review, we will summarize the available data for bispecific antibodies developed and being investigated for the treatment of patients with acute myeloid leukemia.",

keywords = "AML, BiKE, BiTE, Bispecific antibody, DART, Immunotherapy, Tandem antibody, TriKE",

author = "Musa Yilmaz and Farhad Ravandi",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = dec,

doi = "10.1016/j.beha.2020.101218",

language = "English (US)",

volume = "33",

journal = "Best Practice and Research: Clinical Haematology",

issn = "1521-6926",

publisher = "Bailliere Tindall Ltd",

number = "4",

}

TY - JOUR

T1 - The potential role of Bi-specific antibodies in acute myeloid leukemia

AU - Yilmaz, Musa

AU - Ravandi, Farhad

PY - 2020/12

Y1 - 2020/12

N2 - Bispecific antibodies consist of antigen recognition sites from two or more antibodies redirecting effector immune cell against target on tumor cells. Rapidly evolving medical technologies enabled engineering and development of recombinant protein products, and this, combined with interest from the pharmaceutical industry, further advanced the bispecific antibody research. Over 50 different types of bispecific antibody constructs are now being manufactured and explored in ongoing or future clinical trials. In this review, we will summarize the available data for bispecific antibodies developed and being investigated for the treatment of patients with acute myeloid leukemia.

AB - Bispecific antibodies consist of antigen recognition sites from two or more antibodies redirecting effector immune cell against target on tumor cells. Rapidly evolving medical technologies enabled engineering and development of recombinant protein products, and this, combined with interest from the pharmaceutical industry, further advanced the bispecific antibody research. Over 50 different types of bispecific antibody constructs are now being manufactured and explored in ongoing or future clinical trials. In this review, we will summarize the available data for bispecific antibodies developed and being investigated for the treatment of patients with acute myeloid leukemia.

KW - AML

KW - BiKE

KW - BiTE

KW - Bispecific antibody

KW - DART

KW - Immunotherapy

KW - Tandem antibody

KW - TriKE

UR - http://www.scopus.com/inward/record.url?scp=85095735060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095735060&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2020.101218

DO - 10.1016/j.beha.2020.101218

M3 - Review article

C2 - 33279174

AN - SCOPUS:85095735060

SN - 1521-6926

VL - 33

JO - Best Practice and Research: Clinical Haematology

JF - Best Practice and Research: Clinical Haematology

IS - 4

M1 - 101218

ER -

The potential role of Bi-specific antibodies in acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this